D70.2
✓ BillableOther drug-induced agranulocytosis
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
❌ Excludes1
inheritedRules inherited from parent codes in the hierarchy.
- • neutropenic splenomegaly (D73.81)
- • transient neonatal neutropenia (P61.5)
📋 Code Instructions
direct- • code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
📋 Code Instructions
inherited- • code for any associated:
- • fever (R50.81)
Clinical Description
ICD-10-CM code D70.2 represents other drug-induced agranulocytosis. This code falls under the Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89) classification. It is a billable/specific code valid for HIPAA-covered transactions as of October 1, 2025 (FY2026). This code can be used to indicate a diagnosis for reimbursement purposes on insurance claims.
This is a 5-character code at the 4th level of specificity. This is the most specific code available in this subcategory. Coders should note that D70.2 has 2 Excludes1 restriction(s) — codes that cannot be reported together on the same claim.
Frequently Asked Questions
What is ICD-10 code D70.2?
ICD-10-CM code D70.2 is "Other drug-induced agranulocytosis". It belongs to the category: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89).
Is D70.2 a billable ICD-10 code?
Yes, D70.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
What codes are excluded with D70.2?
D70.2 has 2 Excludes1 rule(s). These codes are mutually exclusive and cannot be coded together on the same claim.
Related Codes in D70
Other codes in the same category that may be relevant for differential coding:
🧪 Validate Combinations
Add D70.2 to the Excludes Checker to validate against your full code list.
Open in Checker →Code Information
Data Source
CMS ICD-10-CM 2026 Tabular List
Updated October 1, 2025 (FY2026)